Evidence map›Paper›PMID 37851269›Full record

ArticleActa neuropathologica2023

Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations.

Holly J Roberts, Sunjong Ji, Alberto Picca, Marc Sanson, Mekka Garcia, Matija Snuderl, Ulrich Schüller, Thiébaud Picart, François Ducray, Adam L Green and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. RAS/MAPK inhibition in pediatric gliomas.Neuro-oncology advances · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Diffuse midline glioma with extra central nervous system metastases in the pediatric, adolescent, and young adult population.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Neuro-oncology advances
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Holly J Roberts *Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA.
Sunjong Ji *Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA.
Alberto PiccaDepartment of Neurology-2, Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Marc SansonDepartment of Neurology-2, Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Mekka GarciaDepartment of Neurology, NYU Langone Health, New York, NY, USA.
Matija SnuderlDepartment of Pathology, NYU Langone Health, New York, NY, USA.
Ulrich SchüllerResearch Institute Children's Cancer Center Hamburg, Hamburg, Germany.
Thiébaud PicartDepartment of Neurosurgical Oncology and Vascular Neurosurgery, Pierre Wertheimer Neurological and Neurosurgical Hospital, Hospices Civils de Lyon, Université Lyon 1, CRCL, UMR Inserm 1052, CNRS 5286, 69008, Lyon, France.
François DucrayNeuro-Oncology Department, Hospices Civils de Lyon, Université Lyon 1, CRCL, UMR Inserm 1052, CNRS 5286, 69000, Lyon, France.
Adam L GreenMorgan Adams Foundation Pediatric Brain Tumor Research Program, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.
Yoshiko NakanoDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Dominik SturmHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Zied AbdullaevLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kenneth AldapeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Derek DangDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Chandan Kumar-SinhaDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Yi-Mi WuDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Dan RobinsonDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Josh N VoDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Arul M ChinnaiyanDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Rodrigo CartaxoDepartment of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA.
Santhosh A UpadhyayaDepartment of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA.
Rajen ModyDepartment of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA.
Jason ChiangDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Suzanne BakerDepartment of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA.
David SolomonDepartment of Pathology, University of California, San Francisco, San Francisco, CA, USA.
Sriram VennetiDepartment of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA.
Drew PrattLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Sebastian M Waszak *Laboratory of Computational Neuro-Oncology, School of Life Sciences, Swiss Institute for Experimental Cancer Research, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland. sebastian.waszak@epfl.ch.
Carl Koschmann *Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA. ckoschma@med.umich.edu.ORCID 0000-0002-0825-7615

Funding

The DNA Damage Response and Tumorigenesis in the BrainP01CA096832 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI BAKER, SUZANNE J. · 2003 to 2025
$38.0M
Sequencing, Analysis, and Interpretation of SequencingUM1HG006508 · NHGRI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M, PIENTA, KENNETH J. · 2013 to 2016
$7.8M
SHORT-TERM TRAINING IN HEALTH PROF SCHOOLST35HL007690 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FLAHERTY, KEVIN R · 1990 to 2024
$3.3M
Targeting integrated metabolic and epigenetic pathways in childhood ependymomasR01CA261926 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Deepak Nagrath, Benita Tamrazi · 2022 to 2026
$3.0M
Unravelling metabolic dependencies in H3K27M mutant DIPGR01NS110572 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Sriram Venneti · 2019 to 2026
$2.7M
Targeting EGFR/FOXG1-mediated resistance to ONC201 in H3K27M-mutant diffuse midline gliomaR01NS124607 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Carl J Koschmann · 2022 to 2026
$2.2M
The role of ATRX mutation in the epigenetic dysregulation of cell cycle in pediatric high-grade gliomaR01NS119231 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KOSCHMANN, CARL J · 2021 to 2025
$1.9M
Targeting metabolic dependencies in ZFTA-RELA fusion childhood ependymomasR01NS127799 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Sriram Venneti · 2023 to 2026
$1.8M
NCI NIH HHS P01 CA096832NCI NIH HHS R01 CA261926NHGRI NIH HHS UM1 HG006508NHLBI NIH HHS T35 HL007690NINDS NIH HHS R01 NS110572NINDS NIH HHS R01 NS119231NINDS NIH HHS R01 NS124607NINDS NIH HHS R01 NS127799
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Brain NeoplasmsGliomaEpigenomicsHumansMutation

Identifiers

PMID37851269
PMCPMC10627895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.